Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design

BACKGROUND: The lack of adequate randomized clinical trials (RCT) has hindered identification of new therapies that are safe and effective for patients with primary focal segmental glomerulosclerosis (FSGS), especially in patients who fail to respond to corticosteroids and immunosuppressive therapie...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Trachtman, Howard, Vento, Suzanne, Gipson, Debbie, Wickman, Larysa, Gassman, Jennifer, Joy, Melanie, Savin, Virginia, Somers, Michael, Pinsk, Maury, Greene, Tom
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2011
Matèries:
Study Protocol
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3045306/
https://ncbi.nlm.nih.gov/pubmed/21310077
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2369-12-8
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars